Abstract
The myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic disorders characterized by cytopenias, dysplasia in one or more myeloid lineages, and the potential for development of acute myeloid leukemia. These disorders primarily affect older adults. The NCCN Clinical Practice Guidelines in Oncology for MDS provide recommendations on the diagnostic evaluation and classification of MDS, risk evaluation according to established prognostic assessment tools (including the new revised International Prognostic Scoring System), treatment options according to risk categories, and management of related anemia.
Original language | English (US) |
---|---|
Pages (from-to) | 838-874 |
Number of pages | 37 |
Journal | JNCCN Journal of the National Comprehensive Cancer Network |
Volume | 11 |
Issue number | 7 |
DOIs | |
State | Published - Jul 1 2013 |
ASJC Scopus subject areas
- Oncology